journal
Journals Hematology/oncology and Stem C...

Hematology/oncology and Stem Cell Therapy

https://read.qxmd.com/read/37581467/is-mixed-chimerism-post-allogeneic-hematopoietic-stem-cell-transplantation-in-pediatric-acute-lymphoid-leukemia-a-prognostic-factor-for-relapse
#1
JOURNAL ARTICLE
Saadiya Khan, Zainab AlSaif, Khawar Siddiqui, Hawazen AlSaedi, Ali Al-Ahmari, Abdullah Al-Jefri, Ibrahim Ghemlas, Awatif AlAnazi, Mouhab Ayas
Hematopoietic stem cell transplantation (HSCT) has been considered curative for children with high-risk acute leukemia (ALL), offering better survival. Short tandem repeat has been used as a marker of chimerism status after HSCT. The appearance of recipient cells >1% post-allogeneic stem cell transplant is defined as mixed chimerism (MC). Chimeric studies post-HSCT are dynamic. This study aimed to investigate the significance of recipient cells in post-HSCT pediatric ALL patients as a predictor of relapse of their primary disease...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581466/serum-electrolyte-and-metabolic-changes-during-conditioning-of-autologous-hematopoietic-stem-cell-transplantation-in-patients-with-autoimmune-diseases-a-prospective-study-in-a-single-institution
#2
JOURNAL ARTICLE
Brenda J Méndez-Laureano, Moisés M Gallardo-Pérez, Claudia Minutti-Zanella, Guillermo J Ruiz-Argüelles
BACKGROUND AND OBJECTIVES: A hematopoietic stem cell transplant (HSCT) includes a conditioning regimen which may cause unwanted metabolic changes. We analyzed the changes in electrolytes, glucose, urea, and glomerular filtration rate in patients with multiple sclerosis (MS) who underwent an autologous HSCT employing the "Mexican method." PATIENTS AND METHODS: Serum and urinary electrolytes, blood glucose, creatinine, uric acid, and estimated glomerular filtration rate (eGFR) were prospectively assessed on days -11, -9, and 0 in a group of 75 patients with MS receiving an autologous HSCT employing the "Mexican method," which includes high doses of both cyclophosphamide (Cy, 200 mg/kg) and rituximab (1000 mg)...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581465/comparing-the-safety-and-efficacy-of-intraluminal-brachytherapy-vs-isolated-percutaneous-transhepatic-biliary-drainage-with-internalization-for-unresectable-malignant-biliary-obstruction-a-prospective-observational-study
#3
JOURNAL ARTICLE
Shikha Sood, John V Alexander, Manish Gupta, Ashish Chauhan
BACKGROUND AND OBJECTIVES: Intraluminal therapies, including brachytherapy, can locally destroy obstructing tumors and increase the duration of catheter/stent patency in patients with unresectable malignant biliary obstruction (MBO). In this prospective observational study, the safety and efficacy of percutaneous transhepatic biliary drainage (PTBD) followed by HDR intraluminal brachytherapy (ILBT) in the palliative treatment of malignant biliary obstruction was evaluated. PATIENTS AND METHODS: In total, 66 MBO patients (January 2021 to March 2022) who were unfit for alternate treatment modalities were enrolled in our study and underwent percutaneous transhepatic biliary drainage (PTBD) with internalization...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581464/therapy-related-acute-myeloid-leukemia-in-non-hodgkin-lymphoma-survivors-risk-survival-outcomes-and-prognostic-factor-analysis
#4
JOURNAL ARTICLE
Utsav Joshi, Adheesh Bhattarai, Suman Gaire, Pravash Budhathoki, Vishakha Agrawal, Roshan Subedi, Bishesh S Poudyal, Prajwal Dhakal, Ronald Sham, Vijaya R Bhatt
BACKGROUND: Therapy-related acute myeloid leukemia (tAML) is a serious complication in patients with Non-Hodgkin lymphoma (NHL) exposed to chemotherapy or radiation. This extensive database study aims to quantify the risk of tAML in NHL and determine the impact of tAML on the overall survival (OS) of patients with NHL. MATERIALS AND METHODS: Patients diagnosed with NHL and de novo AML from 2009 to 2018 were identified from the Surveillance, Epidemiology, and End Results database...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581463/role-of-anti-cd38-monoclonal-antibodies-in-the-treatment-of-adult-immune-hematological-diseases
#5
REVIEW
Erin H Yang, Ibrahim N Muhsen, Hadeel Samarkandi, Riad El Fakih, Mahmoud Aljurf, Amr Hanbali
Daratumumab is a first-in-class human anti-CD38 IgG1 monoclonal antibody approved for treating newly diagnosed and relapsed refractory multiple myeloma. Pre-clinical data supported daratumumab's ability to deplete autoantibodies producing plasma cells, B-cells, and NK cells. Those reports showed promising results on using daratumumab in autoimmune disorders that are refractory to multiple lines of therapies, which encouraged using daratumumab in various autoimmune conditions that are refractory to standard therapies...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581462/improved-quality-of-life-of-patients-with-sickle-cell-disease-after-allogeneic-stem-cell-transplant-another-indication-for-transplant
#6
JOURNAL ARTICLE
Bader A Aljaafri, Mohammad F Albawardi, Abdulaziz Y Alghamdi, Khaled M Altowairgi, Yazeed S Alhoshan, Bader Alahmari, Husam Alsadi, Mazin Ahmed, Mohammed Alnahdi, Zied Aljubour, Mohsen Alzahrani
BACKGROUND: Sickle cell disease (SCD) is frequently inherited worldwide. The severity of SCD ranges from mild to severe, and the disease involves multiple complications, including pulmonary hypertension, stroke, recurrent vaso-occlusive crises, end-organ damage, and an increased mortality risk. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option for patients with SCD. OBJECTIVES OF THE STUDY: The objective was to assess the quality of life of adolescent and adult patients with SCD receiving HCT pre-and post-transplant...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581461/fam-trastuzumab-deruxtecan-enhertu-induced-pyloric-perforation-in-hormone-receptor-positive-her2-low-expresses-metastatic-breast-cancer
#7
JOURNAL ARTICLE
Taher Al-Tweigeri
No abstract text is available yet for this article.
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581460/assessing-the-efficacy-of-mitoxantrone-and-doxorubicin-as-frontline-anthracyclines-during-induction-therapy-of-newly-diagnosed-acute-promyelocytic-leukemia
#8
JOURNAL ARTICLE
José C Jaime-Pérez, Eugenia M Ramos-Dávila, Jesús D Meléndez-Flores, Mariana González-Treviño, David Gómez-Almaguer
BACKGROUND: Therapeutic advances in acute promyelocytic leukemia (APL) have transformed it into today's most curable form of leukemia. However, recommended agents, including arsenic trioxide, idarubicin, or daunorubicin, are not easily available in low-middle-income countries, where outcomes remain suboptimal. We aimed to assess the efficacy and safety of more accessible anthracyclines. METHODS: We conducted a retrospective cohort study including sixty-one patients diagnosed with APL over a 15-year period...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581459/invasive-pulmonary-aspergillosis-in-hospitalized-hematopoietic-stem-cell-transplantation-recipients-outcomes-based-on-the-united-states-national-readmission-database
#9
JOURNAL ARTICLE
Amir Khalil, Paramveer Singh, Tanveer Mir, Mohammed Uddin, Ayman O Soubani
BACKGROUND AND OBJECTIVE: Hematopoietic stem cell transplant (HSCT) is a well-established treatment for hematologic malignancies and certain autoimmune and congenital conditions. HSCT is associated with immunocompromise and increased risk of infections. This study assessed whether invasive pulmonary aspergillosis (IPA) affects in-hospital mortality and 30-day readmission among HSCT patients. A secondary objective was to examine potential differences in complications between HSCT with and without IPA...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581458/a-single-center-real-world-experience-of-chronic-gvhd-treatment-using-ibrutinib-imatinib-and-ruxolitinib-and-its-treatment-outcomes
#10
JOURNAL ARTICLE
Swe M Linn, Igor Novitzky-Basso, Omar Abduljalil, Ivan Pasic, Wilson Lam, Arjun Law, Fotios V Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Dennis D H Kim
BACKGROUND: Chronic graft-versus-host disease (cGVHD) is a common cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Tyrosine kinase inhibitors (TKIs), including ruxolitinib, imatinib, and ibrutinib, have shown promising efficacy in cGVHD treatment. METHOD: A total of 43 patients who developed cGVHD and received at least one line of TKI therapy for cGVHD treatment were evaluated retrospectively. The overall response, clinical benefit (CB), corticosteroid dose reduction, failure-free survival (FFS), and overall survival (OS) were assessed...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37581457/side-effects-after-use-of-bedside-thaw-method-for-umbilical-cord-blood-stem-cell-allogeneic-transplantations-in-a-pediatric-cohort-a-single-center-experience
#11
JOURNAL ARTICLE
Natalia Builes, Laura Niño-Serna, Juan F Combariza
BACKGROUND AND OBJECTIVES: Several strategies and procedures have been described for thawing umbilical cord blood (UCB) products. The ideal method for each center depends on the resources, staff training, and access to each of these. We retrospectively evaluated the incidence of side effects using the bedside thaw method after unrelated UCB transplantation. PATIENTS AND METHODS: For 34 children, patient, donor, graft characteristics, and side effects were identified...
July 20, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37399007/application-of-ebmt-mascc-and-qsofa-scores-to-predict-complicated-febrile-neutropenia-and-mortality-in-autologous-stem-cell-transplant-recipients
#12
JOURNAL ARTICLE
Tiago A Barros, Rony Schaffel, Geraldo S de Azevedo Neto, Bianca de Lucena Gaio, Arthur T Batista, Marcia R Valentim, Angelo Maiolino, Marcia Garnica
BACKGROUND AND OBJECTIVES: Three different scores were addressed as predictors of outcomes in autologous stem cell transplant (Auto SCT): one was calculated by pretransplant characteristics (European Society for Blood and Marrow Transplantation [EBMT] risk score), and two were calculated at the onset of febrile neutropenia (Multinational Association for Supportive Care in Cancer [MASCC] and Quick Sequential Organ Failure Assessment [qSOFA]). We considered bloodstream infection (BSI), carbapenem prescription, admission to the intensive care unit (ICU), and mortality as outcomes...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363985/hematologic-manifestations-of-parvovirus-b19-infection
#13
REVIEW
Ghada Algwaiz, Abrar Alharbi, Khuloud Alsehaim, Ali Alahmari, Riad El Fakih, Mahmoud Aljurf
Parvovirus B19 virus infection is widespread among humans because of its highly infectious and obstinate nature, with up to 80% of the population testing positive for IgG antibodies against the virus. Pronormoblasts observed in biopsy are the hallmarks of PVB19 infection. In addition, PVB19 affects the skin, heart, brain, joints, and liver and can be diagnosed through antibody detection or DNA detection via PCR. Due to its capsid proteins' high affinity for bone marrow receptors, its main presentation is the suppression of bone marrow functions...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363984/cytogenetically-normal-acute-myeloid-leukaemia-at-a-single-centre-in-south-africa
#14
JOURNAL ARTICLE
Nicholas Jenkins, Lee-Ann Blanshard, Marian Stone, Estelle Verburgh, Jenna Oosthuizen, Karen Shires
BACKGROUND AND OBJECTIVES: The heterogeneous molecular landscape of cytogenetically normal acute myeloid leukemia (CN-AML) renders it an ongoing therapeutic challenge. The European LeukemiaNet (ELN) 2017 guidelines attempted to address this by guiding post-remission therapy according to six prognostically informative mutations. However, its applicability in a South African setting remains unclear due to limited local data. This retrospective study aimed to describe a South African CN-AML cohort according to clinicopathological and molecular features as well as treatment outcomes and, consequently, to investigate the local applicability of a triple-mutation testing approach for risk stratification in accordance with the ELN 2017 guidelines, using nucleophosmin 1 (NPM1), fms-related receptor tyrosine kinase 3 internal tandem duplication (FLT3-ITD), and CCAAT enhancer-binding protein alpha (CEBPA) mutation status...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363983/post-transplantation-cyclophosphamide-based-graft-versus-host-disease-prophylaxis-compared-to-methotrexate-cyclosporine-a-in-matched-related-allogeneic-hematopoietic-stem-cell-transplantation
#15
JOURNAL ARTICLE
Mohamed T Shouman, Osman M Mansour, Mosaad M El Gammal, Raafat M Abdel-Fattah, Mohamed A Samra, Alaa M Elhaddad, Mohamed A Maher, Hossam K Mahmoud
BACKGROUND AND OBJECTIVES: Post-transplant cyclophosphamide (PTCy) has shown promising results with low rates of severe graft-versus-host-disease (GVHD), either alone or combined with conventional immunosuppression (CIS). However, studies comparing PTCy with CIS as a GVHD prophylaxis are scarce. The study aimed to determine the rates of GVHD and survival outcomes for patients undergoing peripheral blood stem cell transplant (PBSCT) from HLA-matched related donors (MRD) receiving PTCy-based GVHD prophylaxis and compare these outcomes with those of patients receiving methotrexate (MTX) and cyclosporine-A (CsA) as a GVHD prophylaxis...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363982/donor-age-influences-graft-versus-host-disease-relapse-free-survival-after-allogeneic-stem-cell-transplant-in-elderly-patients-in-two-countries-from-latin-america
#16
JOURNAL ARTICLE
Berro Mariano, Nelson Hamerschlak, Milovic Vera, Castro Belén, García P Andrés, Ferini Gonzalo, Real J José, Vitriu Adriana, Gimenez C Alberto, Bendek Georgina, Yantorno Sebastián, Martinez R Juliana, Saslavsky Martin, Jarchum Sol, Cerutti Amalia, Correa da S Cinthya, Rodrigues Morgani, Riera Leandro, Arbelbide Jorge, Kusminsky Gustavo, Basquiera A Lisa
BACKGROUND AND OBJECTIVES: Allogeneic stem cell transplantation (Allo-SCT) in elderly patients is a growing practice. We aimed to determine the graft-versus-host disease (GVHD) relapse-free survival (GRFS) in patients ≥65 years who underwent Allo-SCT in two countries from Latin America. PATIENTS AND METHODS: We performed a retrospective analysis of patients ≥65 years who underwent Allo-SCT in Argentina and Brazil from 2007 to 2019. RESULTS: Ninety-eight patients were evaluated, with primary diagnoses of acute myeloid leukemia and myelodysplastic syndrome; 30% of patients had a hematopoietic cell transplant-comorbidity index (HCT-CI) score ≥3 and 49% were in complete remission...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363981/post-autologous-hematopoietic-cell-transplant-care-in-the-home-sweet-home-setting-a-treatment-paradigm-shift
#17
JOURNAL ARTICLE
Mohamed A Kharfan-Dabaja, Vivek Roy, Hemant Murthy, Deborah Fischer, Razan Mohty, Ashley Greathouse, Alethea Brown, Kathryn Moreno, Emily Godsey, Jennifer M Higginbotham, Ashley Bartholomew, Alexis Jackson, Ricardo A Torres-Guzman, Antonio J Forte, Sikander Ailawadhi, Roxana Dronca, Michael Maniaci
BACKGROUND: Multiple myeloma (MM) is the second most common hematologic malignancy, with 34,470 estimated new cases in 2022. High-dose therapy followed by autologous hematopoietic cell transplantation (auto-HCT) remains a standard treatment for MM even in the era of novel therapies. This is usually performed in hospital-based settings, either in the inpatient or outpatient units. Advanced Care at Home (ACH) represents a virtual hybrid hospital-at-home program that combines a virtual provider-staffed command center with a vendor-mediated supply chain capable of delivering high-acuity care in the comfort of the patients' own homes...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363980/physical-activity-compliance-to-american-cancer-society-recommendations-amongst-hematopoietic-stem-cell-transplant-survivors
#18
JOURNAL ARTICLE
L E Mead, D L Kelly, W J Dahl, J C Colee, Asim Merchant, M T Weaver, John R Wingard, N Farhadfar
BACKGROUND AND OBJECTIVES: The aims of this study were to determine the extent to which hematopoietic cell transplantation (HCT) survivors adhere to the American Cancer Society recommendations for weekly physical activity and identify potential demographic and transplant characteristics associated with the lack of compliance. METHODS: This cross-sectional study included adults who had undergone HCT and were at least 1 year post transplantation. Physical activity was assessed using the screening tool of the Block 2014...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363979/oncotypedx-testing-does-not-benefit-patients-with-estrogen-and-progesterone-receptor-positive-grade-1-breast-cancers-a-tailorx-validated-study
#19
JOURNAL ARTICLE
Udai S Sibia, Charles Mylander, Tasha Martin, Martin Rosman, Thomas J Sanders, Young Lee, Lorraine Tafra, Rubie S Jackson
BACKGROUND & OBJECTIVES: We previously described a predictive AAMC model that identifies patients (grade 1, hormonepositive) who would not benefit from OncotypeDX testing. The purpose of this study was to validate the AAMC model by assessing distant recurrence-free interval (DRFI) and invasive disease-free survival (IDFS) using TAILORx clinical trial data. MATERIALS & METHODS: We retrospectively analyzed TAILORx trial data and categorized patients based on the AAMC model...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/37363978/prevalence-patterns-and-predictors-of-venous-thromboembolic-events-in-patients-undergoing-salvage-chemotherapy-and-autologous-stem-cell-transplantation-for-relapsed-lymphomas
#20
JOURNAL ARTICLE
Mohammad Ma'koseh, Mohammad Alrwashdeh, Nayef Abdel-Razeq, Rozan Alfar, Sarah Edaily, Rayan Bater, Mais Zmaily, Mohammad Almomani, Hikmat Abdel-Razeq
BACKGROUND AND OBJECTIVES: Almost 25% of patients with lymphoma may have relapse or develop refractory disease, and a majority of such patients undergo salvage chemotherapy and autologous stem cell transplantation (ASCT). Data on venous thromboembolism (VTE) in this setting are scarce. This study aimed to investigate the prevalence and factors that may increase the risk of VTE in such patients. PATIENTS AND METHODS: Adult patients who were diagnosed with lymphoma and received salvage chemotherapy and ASCT were included in the study, and the subgroup with radiologically confirmed VTE were identified...
May 23, 2023: Hematology/oncology and Stem Cell Therapy
journal
journal
41905
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.